Recursion cuts several pipeline programs to extend its cash runway

Recursion/Recursion OS and pipeline

In its Q1 2025 update, Recursion deprioritized three clinical programs and one preclinical program after a portfolio review, including discontinuing REC-994 in cerebral cavernous malformation and REC-2282 in NF2. The company reported $509 million in cash and expects to limit 2025 burn below $450 million, extending runway to mid-2027.

• Deprioritized: REC-994 (CCM), REC-2282 (NF2), REC-3964 (unclaimed indication).
• Focus narrowed to 5+ clinical and preclinical programs in oncology and rare disease.
• Q1 2025 cash: $509 million; projected 2025 burn: under $450 million.
• Expected runway extends into mid-2027 post-Exscientia merger.